Literature DB >> 21352939

Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.

Wilbur H Chen1, Alan S Cross, Robert Edelman, Marcelo B Sztein, William C Blackwelder, Marcela F Pasetti.   

Abstract

A comparative analysis of antibody and cell-mediated immune responses was performed in ambulatory medically stable elderly and young adults who received the standard-dose of trivalent inactivated influenza vaccine, containing 15 μg of hemagglutinin (HA) per virus strain, or a high-dose vaccine containing 60 μg HA per virus strain. Among the elderly, the high dose vaccine induced greater HAI (hemagglutination inhibition) and virus neutralization antibody titers than the standard dose vaccine. These responses, however, did not achieve the magnitude of those induced by the standard dose vaccine in young adults. Vaccine-specific circulating T cells producing IFN-γ were detected in the elderly and young adults following immunization. However, there were no significant differences in the IFN-γ responses among groups. On the other hand, the standard dose vaccine in the elderly resulted in the highest proportion of complete non-responders who failed to elicit either an HAI or an IFN-γ response. This study provides further evidence that a higher dose vaccine for the elderly may result in enhanced immune responses which are predicted to improve protection although still of lower magnitude than those induced in younger healthier individuals.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352939      PMCID: PMC3070775          DOI: 10.1016/j.vaccine.2011.02.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

1.  A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

Authors:  Trang Vu; Stephen Farish; Mark Jenkins; Heath Kelly
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

Review 2.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

3.  A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity.

Authors:  F L Ruben; G G Jackson
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

4.  Serum inhibitors of A 2 -Hong Kong influenza virus haemagglutination.

Authors:  K F Shortridge; A Lansdell
Journal:  Microbios       Date:  1972-12

5.  Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation.

Authors:  S R Mostow; S C Schoenbaum; W R Dowdle; M T Coleman; H S Kaye
Journal:  Postgrad Med J       Date:  1973-03       Impact factor: 2.401

6.  Accidental tenfold overdose of influenza vaccine: a clinical and serological study.

Authors:  H Matzkin; E Nili
Journal:  Isr J Med Sci       Date:  1984-05

7.  The senescence-accelerated mouse shows aging-related defects in cellular but not humoral immunity against influenza virus infection.

Authors:  L Dong; I Mori; M J Hossain; Y Kimura
Journal:  J Infect Dis       Date:  2000-07-18       Impact factor: 5.226

8.  Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine.

Authors:  Rosângela Salerno-Goncalves; Marcela F Pasetti; Marcelo B Sztein
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

9.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

Review 10.  Vaccination in the elderly: an immunological perspective.

Authors:  Wilbur H Chen; Bernard F Kozlovsky; Rita B Effros; Beatrix Grubeck-Loebenstein; Robert Edelman; Marcelo B Sztein
Journal:  Trends Immunol       Date:  2009-06-18       Impact factor: 16.687

View more
  31 in total

1.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

2.  Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

Authors:  Wilbur H Chen; Patricia L Winokur; Kathryn M Edwards; Lisa A Jackson; Anna Wald; Emmanuel B Walter; Diana L Noah; Mark Wolff; Karen L Kotloff
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

3.  Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.

Authors:  Shahzma Merani; George A Kuchel; Alison Kleppinger; Janet E McElhaney
Journal:  Exp Gerontol       Date:  2017-09-27       Impact factor: 4.032

4.  Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.

Authors:  David A Nace; Chyongchiou Jeng Lin; Ted M Ross; Stacey Saracco; Roberta M Churilla; Richard K Zimmerman
Journal:  J Infect Dis       Date:  2014-12-17       Impact factor: 5.226

Review 5.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

6.  Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Authors:  Amy Van Ermen; Matthew P Hermanson; John M Moran; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny
Journal:  Eur J Heart Fail       Date:  2013-01-04       Impact factor: 15.534

7.  A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Authors:  Giovanni Della Cioppa; Uwe Nicolay; Kelly Lindert; Geert Leroux-Roels; Frédéric Clement; Flora Castellino; Cristina Galli; Nicola Groth; Yotam Levin; Giuseppe Del Giudice
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

Review 8.  Signals that drive T follicular helper cell formation.

Authors:  Louise M C Webb; Michelle A Linterman
Journal:  Immunology       Date:  2017-07-17       Impact factor: 7.397

9.  On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012.

Authors:  Leah J McGrath; M Alan Brookhart
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.

Authors:  Jin Hyang Kim; H Keipp Talbot; Margarita Mishina; Yuwei Zhu; Jufu Chen; Weiping Cao; Adrian J Reber; Marie R Griffin; David K Shay; Sarah M Spencer; Suryaprakash Sambhara
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.